Matthew Manry, MD
Retina Specialist · Longmont, CONPI 1366735243
Payments from drug & device makers
Across 244 payments — averaging $923.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$130K
- Regeneron$52K
- Apellis Pharmaceuticals, Inc.$31K
- F. Hoffmann-la Roche AG$4K
- AbbVie$3K
- Alimera Sciences, Inc.$1K
- plus $3K from 22 others
Across 8 payments — averaging $168.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 35 | $130,427 |
| Regeneron | 27 | $51,990 |
| Apellis Pharmaceuticals, Inc. | 51 | $31,459 |
| F. Hoffmann-la Roche AG | 2 | $3,794 |
| AbbVie(2 entities) | 11 | $3,276 |
| Alimera Sciences, Inc. | 16 | $1,415 |
| Genentech USA, Inc. | 37 | $728 |
| Eyepoint US, Inc. | 5 | $633 |
| Regeneron Healthcare Solutions, Inc. | 18 | $473 |
| Novartis | 7 | $202 |
| Topcon Healthcare, Inc. | 4 | $191 |
| Astellas Pharma US Inc | 4 | $103 |
| Bausch & Lomb Americas Inc. | 4 | $91 |
| Heidelberg Engineering, Inc. | 2 | $88 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Biogen | 3 | $56 |
| Mallinckrodt Hospital Products Inc. | 3 | $51 |
| Spark Therapeutics, Inc. | 2 | $43 |
| Rxsight Inc | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 2 | $35 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $21 |
| Alcon | 1 | $21 |
| Tarsus Pharmaceuticals, Inc. | 1 | $21 |
| Coherus Oncology, Inc. | 1 | $18 |
| Optos, Inc. | 1 | $16 |
| Glaukos Corporation | 1 | $15 |
| Notal Vision, Inc. | 1 | $12 |
How this compares
$225,306 in reported general payments places this provider in the 65th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Longmont
- Carl NobleLongmont$336K
- Justin KanoffLongmont$14K
- William BenedictLongmont$599
- Sara HaugDurango$9.5M
- James LuuColorado Springs$2.9M
- Mimi LiuEnglewood$2.2M
- Murtaza AdamParker$2.1M
- Ramin SarrafizadehColorado Springs$1.7M
- Brian JoondephDenver$1.6M
- Mark ChittumColorado Springs$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.